Sign up
Pharma Capital

Silence Therapeutics to be a clinical-stage company by year-end

Torsten Hoffmann, chief operating officer at Silence Therapeutics PLC (LON:SLN) chats to Proactive's Andrew Scott following the release of their preliminary 2017 results.

Hoffmann says the big focus for them is working towards filing their first GalNAc-siRNA CTA (clinical trial authorisation) for the treatment of liver-related iron overload disorders by the end of 2018.

Five senior managers have recently been recruited to spearhead the clinical drive.


View full SLN profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.